Compare
Sanara MedTech Inc. vs Establishment Labs Holdings Inc. vs Myomo, Inc. vs Inogen Inc
| Latest fiscal year | Sanara MedTech Inc. SMTI | Establishment Labs Holdings Inc. ESTA | Myomo, Inc. MYO | Inogen Inc INGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $103.12M | $211.08M | $40.93M | $348.67M |
| Revenue growth (YoY) | +19.0% | +27.1% | +25.7% | +3.9% |
| Gross margin | 92.7% | 69.3% | 65.7% | 44.2% |
| Operating margin | 7.1% | -18.5% | -35.2% | -8.7% |
| Net margin | -36.4% | -24.2% | -38.1% | -6.5% |
| Net income | -$37.56M | -$51.06M | -$15.57M | -$22.75M |
| EPS (Diluted) | -$4.36 | -$1.72 | -$0.37 | -$0.86 |
| Operating cash flow | $6.79M | -$50.89M | -$14.51M | -$11.22M |
| Free cash flow | $2.16M | -$56.94M | -$16.25M | -$13.74M |
| Cash & equivalents | $16.58M | $75.57M | $14.13M | $103.73M |
| Total assets | $72.94M | $357.17M | $38.64M | $298.62M |
| Total liabilities | $67.01M | $333.62M | $27.23M | $106.39M |
| Shareholders' equity | $5.94M | $23.55M | $11.40M | $192.23M |
| Return on year-end equity | -632.5% | -216.9% | -136.6% | -11.8% |
| Shares outstanding | 8.95M | 29.30M | 38.47M | 27.23M |
Revenue, most recent five fiscal years
| Fiscal year | Sanara MedTech Inc. | Establishment Labs Holdings Inc. | Myomo, Inc. | Inogen Inc |
|---|---|---|---|---|
| Latest | $103.12M Ended 2025-12-31 | $211.08M Ended 2025-12-31 | $40.93M Ended 2025-12-31 | $348.67M Ended 2025-12-31 |
| 1 year earlier | $86.67M Ended 2024-12-31 | $166.03M Ended 2024-12-31 | $32.55M Ended 2024-12-31 | $335.70M Ended 2024-12-31 |
| 2 years earlier | $64.99M Ended 2023-12-31 | $165.15M Ended 2023-12-31 | $19.24M Ended 2023-12-31 | $315.66M Ended 2023-12-31 |
| 3 years earlier | $45.84M Ended 2022-12-31 | $161.70M Ended 2022-12-31 | $15.56M Ended 2022-12-31 | $377.24M Ended 2022-12-31 |
| 4 years earlier | $24.14M Ended 2021-12-31 | $126.68M Ended 2021-12-31 | $13.86M Ended 2021-12-31 | $358.00M Ended 2021-12-31 |